Home Biosimilar Antibodies Immunology & Inflammation IFN Emapalumab (anti-IFNγ)
For research use only. Not for use in humans.

Emapalumab (anti-IFNγ)

Emapalumab (anti-IFNγ), a monoclonal antibody directed against IFNγ, is the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory.

Emapalumab (anti-IFNγ)

3 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 9.763mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Emapalumab (anti-IFNγ), a monoclonal antibody directed against IFNγ, is the first global approval for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory.
References

Product Details

CAS No. 1709815-23-5
Molecular Weight 135 KD
Isotype Human IgG1
Application Emapalumab (anti-IFNγ)
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05463133 RECRUITING Drug: Sirolimus|Drug: Cyclophosphamide|Drug: Alemtuzumab|Dru Chronic Granulomatous Disease National Institute of Allergy and Infectious Diseases (NIAID) 2022-07-08 PHASE1; PHASE2
NCT07744919 NOT_YET_RECRUITING Drug: Emapalumab Hepatitis Children's Healthcare of Atlanta 2026-09-01 PHASE2
NCT07202598 RECRUITING Drug: Emapalumab Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis National Institute of Allergy and Infectious Diseases (NIAID) 2025-11-12 PHASE2
NCT07244419 RECRUITING Drug: Emapalumab 3 mg/kg|Drug: Emapalumab 10 mg/kg Hematopoietic Stem Cell Transplantation; Graft Failure Children's Hospital Medical Center, Cincinnati 2026-01-07 EARLY_PHASE1
NCT06430788 RECRUITING Aplastic Anemia; Cytopenia; Hypocellular Marrow Memorial Sloan Kettering Cancer Center 2024-05-21 PHASE2
NCT07538336 NOT_YET_RECRUITING Drug: Emapalumab|Drug: Placebo Lung Transplant University of California, San Francisco 2026-11-02 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-05-14)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.